US Stock Market Move | Flagship drug achieves major breakthrough, Kymera Therapeutics (KYMR.US) surges over 40%

On Monday, Kymera Therapeutics (KYMR.US) opened with a surge of over 40%, reaching a historical high of $95.66. On the news front, the expanded phase 1b trial results of KYMR's drug KT-621 for atopic dermatitis showed deep STAT6 degradation in both the 100mg and 200mg dose groups, with median degradation rates of 94% and 98% in skin and blood, respectively, demonstrating strong translational capabilities from healthy volunteers to atopic dermatitis (AD) patients. KT-621 exhibited significant reduction in disease-associated type 2 biomarkers in blood, including thymus and activation-regulated chemokine (TARC) (median decline of 74% in patients comparable to baseline levels in dupilumab AD studies), Eotaxin-3, IL-31, IgE, and core type 2 inflammation and related gene sets in skin lesions. The BROADEN2 phase 2b trial for moderate to severe AD with KT-621 is currently ongoing, and data is expected to be available by mid-2027. The BREADTH phase 2b trial for moderate to severe asthma patients is planned to commence in the first quarter of 2026.